Cysteine protease cathepsin S as a key step in antigen presentation

Drug News and Perspectives

Volumn 17, Issue 6, 2004, Pages 357-363

  Liu, Weimin ^a   Spero, Denice M ^a,b  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^b R and D 6 5 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CATHEPSIN S; CATHEPSIN S INHIBITOR; CHAPERONE; COLLAGEN; COLLAGEN ANTIBODY; CONCANAVALIN A; CYSTATIN C; CYSTEINE PROTEINASE; CYSTEINE PROTEINASE INHIBITOR; FC RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 1BETA; LOW DENSITY LIPOPROTEIN RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MYELIN BASIC PROTEIN; N MORPHOLINUREA LEUCINE HOMOPHENYLALANINE VINYLSULFONE PHENYL; OVALBUMIN; PAPAIN; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTHRITIS; ASTHMA; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CHROMOSOME 1Q; CONTROLLED STUDY; CRYSTAL STRUCTURE; DOWN SYNDROME; EOSINOPHIL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KERATINOCYTE; KNOCKOUT MOUSE; MACROPHAGE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; NORTHERN BLOTTING; PROSTATE CARCINOMA; PROTEIN TARGETING; PSORIASIS; RAT; REVIEW; SJOEGREN SYNDROME; T LYMPHOCYTE;

ANTIGEN PRESENTATION; AUTOIMMUNE DISEASES; CATHEPSINS; CYSTEINE ENDOPEPTIDASES; HUMANS;

EID: 4644335880     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2004.17.6.829027     Document Type: Review

References (83)

1. Germain, R.N. MHC-dependent antigen processing and peptide presentation: Providing ligands for T lymphocyte activation. Cell 1994, 76: 287-99.
2. Unanue, E.R. Antigen-presenting function of the macrophage. Annu Rev Immunol 1984, 2: 395-428.
3. Villadangos, J.A., Bryant, R.A., Deussing, J. et al. Proteases involved in MHC class H antigen presentation. Immunol Rev 1999, 172: 109-20.
4. Riese, R.J. and Chapman, H.A. Cathepsins and compartmentalization in antigen presentation. Curr Opin Immunol 2000, 12: 107-13.
5. Turk, V., Turk, B. and Turk, D. Lysosomal cysteine proteases: Facts and opportunities. EMBO J 2001, 20: 4629-33.
6. Nakagawa, T.Y. and Rudensky, A.Y. The role of lysosomal proteinases in MHC class II-mediated antigen processing and presentation. Immunol Rev 1999, 172: 121-9.
7. McGrath, M.E. The lysosomal cysteine proteases. Annu Rev Biophys Struct 1999, 28: 181-204.
8. Shi, G.P., Sukhova, G.K., Kuzuya, M. et al. Deficiency of the cysteine protease cathepsin S impairs microvessel growth. Circ Res 2003, 92: 493-500.
9. Sukhova, G.K., Zhang, Y., Pan, J.H. et al. Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2003, 111: 897-906.
10. Turk, B., Stoka, V., Rozman-Pungercar, J. et al. Apoptotic pathways: Involvement of lysosomal proteases. Biol Chem 2002, 383: 1035-44.
11. Chapman, H.A., Riese, R.J. and Shi, G.P. Emerging roles for cysteine proteases in human biology. Annu Rev Physiol 1997, 59: 63-88.
12. Riese, R.J., Wolf, P.R., Bromme, D. et al. Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. Immunity 1996, 4: 357-66.
13. Tumsek, T., Kregar, I. and Lebez, D. Acid sulfhydryl protease from calf lymph nodes. Biochim Biophys Acta 1975, 403: 514-20.
14. Wiederanders, B., Brömme, D., Kirschke, H. et al. Phylogenetic conservation of cysteine proteinases. Cloning and expression of a cDNA coding for human cathepsin S. J Biol Chem 1992, 267: 13708-13.
15. Shi, G.-P., Munger, J.S., Meara, J.P. et al. Molecular cloning and expression of human alveolar macrophage cathepsin S, an elastinolytic cysteine protease. J Biol Chem 1992, 267: 7258-62.
16. Shi, G.P., Webb, A.C., Foster, K.E. et al. Human cathepsin S: Chromosomal localization, gene structure and tissue distribution. J Biol Chem 1994, 269: 11530-6.
17. Linnevers, C., Smeekens, S.P. and Brömme, D. Human cathepsin W, a putative cysteine protease predominantly expressed in CD8+ T-lymphocytes. FEBS Lett 1997, 405: 253-9.
18. Jokimaa, V., Oksjoki, S., Kujari, H. et al. Expression patterns of cathepsins B, H, K, L and S in the human endometrium. Mol Hum Reprod 2001, 7: 73-8.
19. Barrera, C., Ye, G., Espejo, R. et al. Expression of cathepsin B, L, S and D by gastric epithelial cells implicates them as antigen presenting cells in local immune responses. Hum Immunol 2001, 62: 1081-91.
20. Zurdel, J., Finckh, U., Menzer, G. et al. CST3 genotype associated with exudative age related macular degeneration. Br J Ophthalmol 2002, 86: 214-9.
21. Petanceska, S., Bruke, S., Watson, S.J. et al. Differential distribution of messenger RNAs for cathepsins B, L and S in adult rat brain: An in situ hybridization study. Neuroscience 1994, 59: 728-39.
22. Greiner, A., Lautwein, A., Overkleeft, H.S. et al. Activity and subcellular distribution of cathepsin in primary human monocytes. J Leukoc Biol 2003, 73: 235-42.
23. Fengler, A. and Brandt, W. Three-dimensional structures of the cysteine proteases cathepsins K and S deduced by knowledge-based modelling and active site characteristics. Protein Eng 1998, 11: 1007-13.
24. McGrath, M.E., Palmer, J.T., Bromme, D. et al. Crystal structure of human cathepsin S. Protein Sci 1998, 7: 1294-302.
25. Ward, Y.D., Thomson, D.S., Frye, L.L. et al. Design and synthesis of dipeptide nitriles as reversible and potent cathepsin S inhibitors. J Med Chem 2002, 45: 5471-82.
26. Turkenburg, J.P., Lamers, M.B., Brzozowski, A.M. et al. Structure of a Cys25 Ser mutant of human cathepsin S. Acta Crystallogr 2002, 58: 451-5.
27. Pauly, T.A., Sulea, T., Ammirati, M. et al. Specificity determinants of human cathepsin S revealed by crystal structures of complexes. Biochemistry 2003, 42: 3203-13.
28. Leung, D., Abbenante, G. and Fairlie, D.P. Protease inhibitors: Current status and future prospects. J Med Chem 2000, 43: 305-41.
29. Brömme, D., Bonneau, P.R., Lachance, P. et al. Functional expression of human cathepsin S in saccharomyces cerevisiae. J Biol Chem 1993, 286: 4832-8.
30. Kirshke, H., Wiederanders, B., Brömme, D. et al. Cathepsin S from bovine spleen. Biochem J 1989, 264: 467-73.
31. Brömme, D., Steinert, A., Friebe, S. et al. The specificity of bovine spleen cathepsin S. A comparison with rat liver cathepsin L and B. Biochem J 1989, 264: 475-81.
32. Xin, X.Q., Gunesekera, B. and Mason, R.W. The specificity and elastinolytic activities of bovine cathepsins S and H. Arch Biochem Biophys 1992, 299: 334-9.
33. Beck, H., Schwarz, G. Schroter, C.J. et al. Cathepsin S and asparagine-specific endoprotease dominate the proteolytic processing of human myelin basic protein in vitro. Eur J Immunol 2001, 31: 3726-36.
34. Riese, R.J., Wolf, P.R., Brömme, D. et al. Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. Immunity 1996, 4: 357-66.
35. Cresswell, P. Chemistry and functional role of the invariant chain. Curr Opin Immunol 1992, 4: 87-92.
36. Germain, R.N. and Rinker, A.G. Peptide binding inhibits protein aggregation of invariant-chain free class II dimmers and promotes surface expression of occupied molecules. Nature 1993, 363: 275-8.
37. Lotteau, V., Teyton, L., Peleraux, A. et al. Intracellular transport of class II MHC molecules directed by invariant chain. Nature 1990, 348: 600-5.
38. Bakke, O. and Dobberstein, B. MHC class II-associated invariant chain contains a sorting signal for endosomal compartments. Cell 1990, 63: 707-16.
39. Denzin, L.K. and Cresswell, P. HLA-DM induces CLIP dissociation from MHC class II alpha-beta dimmers and facilitates peptide loading. Cell 1995, 82: 155-65.
40. Sercarz, E.E. and Maverakis, E. MHC-guided processing binding of large antigen fragments. Nat Rev Immunol 2003, 3: 621-9.
41. Robinson, J.H. and Delvig, A.A. Diversity in MHC class II antigen presentation. Immunology 2002, 105: 252-62.
42. Riese, R.J., Mitchell, R.N., Valladangos, J.A. et al. Cathepsin S activity regulates antigen presentation and immunity. J Clin Invest 1998, 101: 2351-63.
43. Villadangos, J.A., Riese, R.J., Peters, C. et al. Degradation of mouse invariant chain: Roles of cathepsins S and D and the influence of major histocompatibility complex polymorphism. J Exp Med 1997, 186: 549-60.
44. Deussing, J., Roth, W., Saftig, P. et al. Cathepsins B and D are dispensable for major histocompatibility complex class II-mediated antigen presentation. Proc Natl Acad Sci USA 1998, 95: 4516-21.
45. Shi, G.P., Villadangos, J.A., Dranoff, G. et al. Cathepsin S required for normal MHC class II peptide loading and germinal center development. Immunity 1999, 10: 197-206.
46. Nakagawa, T.Y., Brissette, W.H., Lira, P.D. et al. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity 1999, 10: 207-17.
47. Nakagawa, T., Roth, W., Wong, P. et al. Cathepsin L: Critical role in Ii degradation and CD4 T cell selection in the thymus. Science 1998, 280: 450-3.
48. Villadangos, J.A., Bryant, R.A.R., Deussing, J. et al. Proteases involved in MHC class II antigen presentation. Immunol Rev 1999, 172: 109-20.
49. Shi, G.P., Bryant, A.R., Riese, R. et al. Role for Cathepsin F in invariant chain processing and major histocompatibility complex class II peptide loading by macrophages. J Exp Med 2000, 191: 1177-85.
50. Banchereau, J. and Steinman, R.M. Dendritic cells and the control of immunity. Nature 1998, 392: 245-52.
51. Driesen, C., Bryant, R.A.R., Lennon-Dumenil, A.M. et al. Cathepsin S controls the trafficking and maturation of MHC class II molecules in dendritic cells. J Cell Biol 1999, 147: 775-90.
52. Pierre, P. and Mellman, I. Development regulation of variant chain proteolysis controls MHC class II trafficking in mouse dendritic cells. Cell 1998, 93: 1135-45.
53. Villadangos, J.A., Cardoso, M., Steptoe, R.J. et al. MHC class II expression is regulated in dendritic cells independently of variant chain degradation. Immunity 2001, 14: 739-49.
54. Bania, J., Gatti, E., Lelouard, H. et al. Human cathepsin S, but not cathepsin L, degrades efficiently MHC class II-associated invariant chain in nonprofessional APCs. Proc Natl Acad Sci USA 2003, 100: 6664-9.
55. Gresser, O., Weber, E., Hellwig, A. et al. Immunocompetent astrocytes and microglia display major differences in the processing of the variant chain in the expression of active cathepsin L and cathepsin S. Eur J Immunol 2001, 31: 1813-24.
56. Wiendl, H., Lautwein, A., Mitsdorffer, M. et al. Antigen processing and presentation in human muscle: Cathepsin S is critical for MHC class II expression and upregulated in inflammatory myopathies. J Neuroimmunol 2003, 138: 132-43.
57. Driessen, D., Lennon-Duménil, A.-M. and Ploegh, H.L. Individual cathepsins degrade immune complexes internalized by antigen-presenting cells via Fc gamma receptors. Eur J Immunol 2001, 31: 1592-601.
58. Plüger, E.B., Boes, M., Alfonso, C. et al. Specific role for cathepsin S in the generation of antigenic peptides in vivo. Eur J Immunol 2002, 32: 467-76.
59. Hsieh, C.-S., deRoos, P., Honey, K. et al. A role for cathepsin L and cathepsin S in peptide generation for MHC class II presentation. J Immunol 2002, 168: 2618-25.
60. Allen, E., Vitali, N., Underwood, S. et al. Reversible cathepsin S (Cat S) inhibitors block invariant chain processing in vitro and reduced the severity of collagen-induced arthritis (CIA) in vivo. Inflamm Res 2002, 51(Suppl 2): S121, A1.
61. Wucherpfenning, K.W., Catz, I., Hausmann, S. et al. Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2-restricted T cell clones from multiple sclerosis patients. Identity of key contact residues in the B-cell and T-cell epitopes. J Clin Invest 1997, 100: 1114-22.
62. Liuzzo, J.P., Pentaceska, S.S. and Devi, L.A. Neurotrophic factors regulate cathepsin S in macrophages and microglia: A role in the degradation of myelin basic protein and amyloid beta peptide. Mol Med 1999, 5: 334-43.
63. Davis, G. and Jeij, I. Modulation of experimental autoimmune encephalomyelitis (EAE) by a non-peptide inhibitor for cathepsin S. Inflamm Res 2002, 51(Suppl 2): Abst A5.
64. Schwarz, G., Boehncke, W.H., Braun, M. et al. Cathepsin S activity is detectable in human keratinocytes and is selectively upregulated upon stimulation with interferon-gamma. J Invest Dermatol 2002, 119: 44-9.
65. Szabo, S.K., Hammerberg, C., Yoshida, Y. et al. Identification and quantitation of interferon-gamma producing T cells in psoriatic lesions: Localization of both CD4+ and CD8+ subsets. J Invest Dermatol 1998, 111: 1072-8.
66. Petanceska, S., Burke, S., Watson, S.J. et al. Differential distribution of messenger RNAs for cathepsins B, L and S in adult rat brain: An in situ hybridization study. Neuroscience 1994, 59: 729-38.
67. Lemere, C.A., Munger, J.S., Shi, G.P. et al. The lysosomal cysteine protease, cathepsin S, is increased in Alzheimer's disease and Down syndrome brain. An immunocytochemical study. Am J Pathol 1995, 146: 848-60.
68. Munger, J.S., Haass, C., Lemere, C.A. et al. Lysosomal processing of amyloid precursor protein to Abeta peptides: A distinct role for cathepsin S. Biochem J 1995, 311: 290-305.
69. Saegusa, K., Ishimaru, N., Yanagi, K. et al. Cathepsins S inhibitor prevents autoantigen presentation and autoimmunity. J Clin Invest 2002, 110: 361-9.
70. Cai, H., Edwards, J.P., Gu, Y. et al. Use of 1-(piperazin-1-yl) alkyl-3-phenylpyrazole cathepsin S inhibitors in methods of treating allergies. PCT Int Appl 2002, WO 0220013.
71. Podolin, P.L., Capper, E.A., Bolognese, B.J. et al. Cathepsin S inhibitors block invariant chain processing and antigen-induced proliferation in vitro, and inhibit murine collagen-induced arthritis (CIA) and rat ovalbumin-induced asthma in vivo. Inflamm Res 2002, 51(Suppl 2): S133, A76.
72. Cimerman, N., Brguljan, P.M., Krasovec, M. et al. Circadian and concentration profile of cathepsin S in sera from healthy subjects and asthmatic patients. Pflügers Arch 2001, 442(6 Suppl 1): R204-6.
73. Donnelly, L.E. and Rogers, D.F. Therapy for chronic obstructive pulmonary disease in the 21st century. Drugs 2003, 63: 1973-8.
74. Shapiro, S.D. Proteinase in chronic obstructive pulmonary disease. Biochem Soc Trans 2001, 30: 98-102.
75. Fernandez, P.L., Farre, X., Nadal, A. et al. Expression of cathepsin B and S in the progression of prostate carcinoma. Int J Cancer 2001, 95: 51-5.
76. Kos, J., Sekimik, A., Kopitar, G. et al. Cathepsin S in tumours, regional lymph nodes and sera of patients with lung cancer: Relation to prognosis. Br J Cancer 2001, 85: 1193-200.
77. Sukhova, G.K., Shi, G.-P. Simon, D.I. et al. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest 1998, 102: 576-83.
78. Fos, J.H., Burns-Kurtis, C.L., Needle, S. et al. A role for cathepsin in atherosclerosis. Inflamm Res 2002, 51(Suppl 2): S130, A57.
79. Villadangos, J.A. Presentation of antigens by MHC class II molecules: Getting the most out of them. Mol Immunol 2001, 38: 329-46.
80. Honey, K. and Rodensky, A.Y. Lysosomal cysteine proteases regulate antigen presentation. Nat Rev Immunol 2003, 3: 472-82.
81. Kim, W. and Kang, K. Recent developments of cathepsin inhibitors and their selectivity. Expert Opin Ther Patents 2002, 12: 419-32.
82. Brömme, D. and Kaleta, J. Thiol-dependent cathepsins: Pathophysiological implications and recent advances in inhibitor design. Curr Pharm Des 2002, 8: 1639-58.
83. Leung-Toung, R., Li, W., Tam, T.F. et al. Thiol-dependent enzymes and their inhibitors: A review. Curr Med Chem 2002, 9: 879-1002.